Antibody molecules to TIM-3 and uses thereof

US9884913B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• DANA-FARBER CANCER INSTITUTE, INC. · US
• Children's Medical Center Corporation · US

Inventors

• Catherine Anne Sabatos-Peyton · Cambridge, US
• Barbara Brannetti · Basel, CH
• Alan S. Harris · Andover, US
• Thomas Huber · Basel, CH
• Thomas Pietzonka · Basel, CH
• Jennifer Marie Mataraza · Cambridge, US
• Walter A. Blattler · Brookline, US
• Daniel Hicklin · Montclair, US
• Maximiliano Vasquez · Palo Alto, US
• Rosemarie Dekruyff · Newton, US
• Dale T. Umetsu · Stanford, US
• Gordon J. Freeman · Brookline, US
• Tiancen Hu · Cambridge, US
• John A. Taraszka · Cambridge, US
• Fangmin Xu · Cambridge, US

Key dates

• Filing date: Mar 17, 2017
• Grant date: Feb 6, 2018
• Expiry date: Mar 17, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.